Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.35 |
| ▸ | FDPS | P14324 | 9/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25101330 | 0.76 | TSHR (0.38) | TSHRTHRBGGPS1FDPSSMPD1 | |
| Ammonia Solution, Strong SCHEMBL6037107 | 0.75 | TSHR (0.35) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL2348711 | 0.74 | GGPS1 (0.39) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL12159929 | 0.74 | OPRM1 (0.41) | TSHRTHRBGGPS1FDPSDNM1 | |
| SCHEMBL8651140 | 0.74 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL7757197 | 0.74 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL5687998 | 0.74 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL17529752 | 0.74 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL14422028 | 0.74 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL1178287 | 0.74 | TSHR (0.47) | TSHRTHRBGGPS1FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925868-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10702504-B2 | Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190209535-A1 | DEGRADATION OF TRIPARTITE MOTIF-CONTAINING PROTEIN 24 (TRIM24) BY CONJUGATION OF TRIM24 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209535-A1 | DEGRADATION OF TRIPARTITE MOTIF-CONTAINING PROTEIN 24 (TRIM24) BY CONJUGATION OF TRIM24 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TRIM24, TRIM4, TRIM33 | TSHR 3904/4885THRB 1875/4885GGPS1 3914/4885 |
| US-10925868-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | MDM2, DSTYK, MAP2K2 | TSHR 3711/4885THRB 1376/4885GGPS1 3889/4885 |
| US-10702504-B2 | Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use | TRIM24, TRIM4, TRIM33 | TSHR 3904/4885THRB 1875/4885GGPS1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.